Bavarian Nordic A/S (BV3.F)

31,30 -0,50 (-1,57%) Börsenschluss: 09:39PM CEST

Bavarian Nordic A/S

Philip Heymans Alle 3
Hellerup 2900
Denmark
45 33 26 83 83
https://www.bavarian-nordic.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 1.381

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Paul John Chaplin MSc, Ph.D.	CEO & President	1,96M	N/A	1967
Mr. Henrik Juuel M.Sc.	CFO & Executive VP	1,08M	N/A	1965
Mr. Russell Thirsk M.Sc.	Executive VP & COO	N/A	N/A	1968
Mr. Rolf Sass Sørensen	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Ms. Anu Helena Kerns M.Sc.	Executive VP and Chief People & Sustainability Officer	N/A	N/A	1972
Mr. Jean-Christophe May M.B.A., Pharm.D.	Executive VP & Chief Commercial Officer	N/A	N/A	1967

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Corporate Governance

Bavarian Nordic A/Ss ISS Governance QualityScore, Stand 1. September 2024, lautet 4. Die grundlegenden Scores sind Audit: 4, Vorstand: 1, Shareholderrechte: 1, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.